darleukin (L19IL2) / Philogen 
Welcome,         Profile    Billing    Logout  
 13 Diseases   3 Trials   3 Trials   53 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
darleukin (L19IL2) / Philogen
Pivotal, NCT02938299 / 2015-002549-72: Neoadjuvant L19IL2/L19TNF- Study

Recruiting
3
214
Europe
L19IL2 + L19TNF, Surgery
Philogen S.p.A.
Malignant Melanoma
10/24
12/25
2020-003299-42: Intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients

Not yet recruiting
2
92
Europe
Bifikafusp alfa, onfekafusp alfa, L19IL2, L19TNF, Solution for injection
Philogen S.p.A., Philogen S.p.A.
Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery according to the evaluation of a local interdisciplinary tumor board or who refuse surgery and for whom an histological evaluation is available according to international guidelines, Non melanoma skin cancer, Diseases [C] - Cancer [C04]
 
 
IMMUNOSABR2, NCT03705403 / 2018-002583-11: IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study

Active, not recruiting
2
88
Europe
Darleukin, L19 - IL2, Radiation, Radiotherapy
Maastricht University Medical Center, Academisch Ziekenhuis Maastricht, The Netherlands Cancer Institute, University Medical Center Nijmegen, Erasmus Medical Center, University Ghent, KU Leuven, Centre Oscar Lambret, Gasthuis Zusters Antwerpen, University College, London, Cliniques universitaires Saint-Luc- Université Catholique de Louvain, University Hospital Dresden, University Hospital Tuebingen, Heidelberg University, Catholic University of the Sacred Heart, Institut du Cancer de Montpellier - Val d'Aurelle
NSCLC Stage IV, Metastatic Disease
01/25
01/25
IntriNSiC, NCT05329792 / 2021-006041-36: L19IL2/L19TNF in Skin Cancer Patients

Recruiting
2
70
Europe
L19IL2/L19TNF, bifikafusp alfa/onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
06/24
12/24
NCT02076646: A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Active, not recruiting
1/2
96
Europe
L19IL2 - Ph I, L19IL2 at RD - Ph II, DTIC, DETICENE®
Philogen S.p.A.
Metastatic Melanoma Stage IV
05/16
06/22
NCT02957019 / 2014-001949-25: A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Terminated
1/2
6
Europe
L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
Philogen S.p.A.
Diffuse Large B-cell Lymphoma (DLBCL)
09/23
09/23

Download Options